Cargando…
Delayed anticoagulation in venous thromboembolism: Reasons and associated outcomes
OBJECTIVE: We assessed the number of cases with delayed anticoagulation initiation, explored the reasons for the delay, and its impact on outcome in patients with acute venous thromboembolism (VTE) treated in an organized setting of treatment initiation and continuous, prospective follow‐up. METHODS...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117818/ https://www.ncbi.nlm.nih.gov/pubmed/34027287 http://dx.doi.org/10.1002/rth2.12500 |
_version_ | 1783691647111921664 |
---|---|
author | Brunton, Nichole E. Wysokinski, Waldemar E. Hodge, David O. Vlazny, Danielle T. Houghton, Damon E. Casanegra, Ana I. |
author_facet | Brunton, Nichole E. Wysokinski, Waldemar E. Hodge, David O. Vlazny, Danielle T. Houghton, Damon E. Casanegra, Ana I. |
author_sort | Brunton, Nichole E. |
collection | PubMed |
description | OBJECTIVE: We assessed the number of cases with delayed anticoagulation initiation, explored the reasons for the delay, and its impact on outcome in patients with acute venous thromboembolism (VTE) treated in an organized setting of treatment initiation and continuous, prospective follow‐up. METHODS: Patients with anticoagulation initiation delay >24 hours were identified within the cohort of patients with acute VTE enrolled in the Mayo Clinic Venous Thromboembolism Registry between 2013 and 2020. The reasons for treatment delay were explored by reviewing the electronic database. VTE recurrence, all‐cause mortality, major bleeding, and clinically relevant nonmajor bleeding (CRNMB) were compared to those with no anticoagulation delay. RESULTS: Of 2378 patients with acute VTE, 100 (4.2%) experienced an anticoagulation delay. We identified seven reasons for treatment delays: deferring anticoagulation initiation to specialists (n = 38), thrombocytopenia (n = 10), planned or recent procedure (n = 16), active or recent bleeding (n = 12), missed diagnosis (n = 7), logistics (n = 6), and patient decision (n = 4). In seven cases, no reason was identified. We identified modifiable reasons for anticoagulation delay in 55%. At 90‐day follow‐up, patients with anticoagulation delay had a higher rate of mortality and major bleeding. VTE recurrence and CRNMB were not statistically different compared to those without anticoagulation delay. After adjustment for age, weight, and cancer, hazard ratios (HRs) for VTE recurrence and major bleeding remained elevated but not to a statistically significant level. CONCLUSION: In the setting of a highly organized system of anticoagulation initiation, the incidence of treatment delay is low. Yet most delays could be avoided. A low number of cases provide insufficient power to evaluate the clinical consequences of anticoagulation initiation delay; however, elevated HR for VTE recurrence and major bleeding suggest association and need for further investigation. |
format | Online Article Text |
id | pubmed-8117818 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81178182021-05-20 Delayed anticoagulation in venous thromboembolism: Reasons and associated outcomes Brunton, Nichole E. Wysokinski, Waldemar E. Hodge, David O. Vlazny, Danielle T. Houghton, Damon E. Casanegra, Ana I. Res Pract Thromb Haemost Original Articles OBJECTIVE: We assessed the number of cases with delayed anticoagulation initiation, explored the reasons for the delay, and its impact on outcome in patients with acute venous thromboembolism (VTE) treated in an organized setting of treatment initiation and continuous, prospective follow‐up. METHODS: Patients with anticoagulation initiation delay >24 hours were identified within the cohort of patients with acute VTE enrolled in the Mayo Clinic Venous Thromboembolism Registry between 2013 and 2020. The reasons for treatment delay were explored by reviewing the electronic database. VTE recurrence, all‐cause mortality, major bleeding, and clinically relevant nonmajor bleeding (CRNMB) were compared to those with no anticoagulation delay. RESULTS: Of 2378 patients with acute VTE, 100 (4.2%) experienced an anticoagulation delay. We identified seven reasons for treatment delays: deferring anticoagulation initiation to specialists (n = 38), thrombocytopenia (n = 10), planned or recent procedure (n = 16), active or recent bleeding (n = 12), missed diagnosis (n = 7), logistics (n = 6), and patient decision (n = 4). In seven cases, no reason was identified. We identified modifiable reasons for anticoagulation delay in 55%. At 90‐day follow‐up, patients with anticoagulation delay had a higher rate of mortality and major bleeding. VTE recurrence and CRNMB were not statistically different compared to those without anticoagulation delay. After adjustment for age, weight, and cancer, hazard ratios (HRs) for VTE recurrence and major bleeding remained elevated but not to a statistically significant level. CONCLUSION: In the setting of a highly organized system of anticoagulation initiation, the incidence of treatment delay is low. Yet most delays could be avoided. A low number of cases provide insufficient power to evaluate the clinical consequences of anticoagulation initiation delay; however, elevated HR for VTE recurrence and major bleeding suggest association and need for further investigation. John Wiley and Sons Inc. 2021-04-07 /pmc/articles/PMC8117818/ /pubmed/34027287 http://dx.doi.org/10.1002/rth2.12500 Text en © 2021 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Brunton, Nichole E. Wysokinski, Waldemar E. Hodge, David O. Vlazny, Danielle T. Houghton, Damon E. Casanegra, Ana I. Delayed anticoagulation in venous thromboembolism: Reasons and associated outcomes |
title | Delayed anticoagulation in venous thromboembolism: Reasons and associated outcomes |
title_full | Delayed anticoagulation in venous thromboembolism: Reasons and associated outcomes |
title_fullStr | Delayed anticoagulation in venous thromboembolism: Reasons and associated outcomes |
title_full_unstemmed | Delayed anticoagulation in venous thromboembolism: Reasons and associated outcomes |
title_short | Delayed anticoagulation in venous thromboembolism: Reasons and associated outcomes |
title_sort | delayed anticoagulation in venous thromboembolism: reasons and associated outcomes |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117818/ https://www.ncbi.nlm.nih.gov/pubmed/34027287 http://dx.doi.org/10.1002/rth2.12500 |
work_keys_str_mv | AT bruntonnicholee delayedanticoagulationinvenousthromboembolismreasonsandassociatedoutcomes AT wysokinskiwaldemare delayedanticoagulationinvenousthromboembolismreasonsandassociatedoutcomes AT hodgedavido delayedanticoagulationinvenousthromboembolismreasonsandassociatedoutcomes AT vlaznydaniellet delayedanticoagulationinvenousthromboembolismreasonsandassociatedoutcomes AT houghtondamone delayedanticoagulationinvenousthromboembolismreasonsandassociatedoutcomes AT casanegraanai delayedanticoagulationinvenousthromboembolismreasonsandassociatedoutcomes |